IJIMM, Volume 3, Issue 7, 2025 ISSN: 2995-5319
http://medicaljournals.eu/index.php/IJIMM/issue/view/3

INTERNATIONAL JOURNAL OF INTEGRATIVE AND MODERN MEDICINE

The Neuropharmacology of Pain Management: New Insights and Therapeutic Approaches

Zulfkar Qadrie
Department of Pharmacology, Government Medical College Baramulla

Humaira Ashraf
Department of Animal Nutrition, SKUAST-K, Srinagar, India

Mohd Altaf Dar
Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab

Abstract: Pain is a complex sensory and emotional experience that significantly impacts an individual's quality of life. It often arises from underlying pathophysiological processes and can present as acute or chronic pain, each involving distinct mechanisms. The neuropharmacology of pain management seeks to understand the molecular, cellular, and neurological pathways involved in pain perception and how these can be modulated through pharmacological interventions. Traditional pain management strategies, including opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and local anesthetics, have provided relief but come with limitations such as side effects, tolerance, and dependency. Recent advancements in neuroscience and pharmacology have led to the development of novel therapeutic approaches that target specific receptors, ion channels, and signaling pathways involved in pain transmission. These new therapies aim to provide more effective and precise pain relief while minimizing adverse effects. Key molecular targets, including ion channels like TRPV1, NMDA receptors, and cannabinoid receptors, are being explored to improve the management of various pain types, especially chronic and neuropathic pain. This review discusses recent insights into the neuropharmacology of pain, emphasizing new targets, mechanisms, and drugs that show promise in enhancing pain management in clinical settings. We also address ongoing challenges, including drug efficacy, side effects, and the need for individualized treatment strategies. The evolving landscape of pain management offers hope for more effective, safer therapies, which could significantly improve the quality of life for patients suffering from both acute and chronic pain.

Keywords: pain management, neuropharmacology, pain receptors, ion channels, therapeutic approaches, drug efficacy, chronic pain, pharmacological interventions, signaling pathways.

1. Introduction

Pain is a complex, multifaceted sensory and emotional experience that plays a crucial role in alerting the body to potential injury or harm. It serves as a protective mechanism, prompting individuals to withdraw from harmful stimuli and seek medical intervention when necessary. Acute pain, resulting from immediate tissue damage or injury, typically subsides once the injury heals. However, in some cases, pain can become pathological and persist long after the original injury has resolved, or it may arise without any clear physical cause. This is the case in **chronic pain** disorders such as **neuropathic pain**, **fibromyalgia**, **migraine**, and **osteoarthritis**, which affect millions of individuals worldwide and often result in long-term suffering, disability, and impaired quality of life [1]. The burden of chronic pain is significant, affecting not only individuals but also society at large, with associated healthcare costs, loss of productivity, and psychological consequences such as depression and anxiety. Chronic pain is often difficult to manage effectively, and many individuals continue to experience persistent pain despite ongoing treatment efforts. As a result, chronic pain remains one of the most challenging medical conditions to treat. The neuropharmacology of pain seeks to address this challenge by exploring how pain is processed in the nervous system and identifying ways to modulate pain pathways with drugs. The nervous system processes pain through a series of complex mechanisms

involving **nociceptors** (pain receptors), **spinal cord processing**, and the **brain's interpretation of pain signals [2]**. When the body experiences harmful stimuli, nociceptors detect the injury and send electrical signals to the spinal cord and brain, where the sensation of pain is perceived. These pain signals can be modified by various factors, including inflammation, neural plasticity, and neurotransmitter activity. In chronic pain, these mechanisms become dysregulated, leading to heightened sensitivity to pain or the perception of pain without any external injury, a phenomenon known as **central sensitization**. The study of the **neuropharmacology of pain** aims to identify the molecular, cellular, and neural mechanisms that underlie pain perception and how these mechanisms can be modulated pharmacologically to provide pain relief. Research has led to a better understanding of the pathways involved in pain and the development of various pharmacological treatments designed to alleviate pain. These treatments range from **opioids** and **non-steroidal anti-inflammatory drugs (NSAIDs)** to newer classes of drugs that target specific receptors, ion channels, and signaling pathways involved in pain transmission [3].

Despite the availability of several pain management strategies, significant challenges remain in the effective treatment of pain. One of the most widely used classes of pain-relieving drugs, **opioids**, has been the mainstay for treating moderate to severe pain, particularly in cases of cancer pain, post-surgical pain, and acute injuries. Opioids work by binding to specific receptors in the **central nervous system**, blocking pain signals and producing feelings of analgesia and euphoria. However, opioids come with significant risks, including **addiction**, **tolerance**, **dependence**, and **overdose**, which has contributed to the opioid crisis. Additionally, not all patients respond to opioids with sufficient efficacy, and many experience side effects such as **constipation**, **sedation**, **nausea**, and **respiratory depression [4]**. Due to these risks, there has been a growing need for alternative treatments with a better safety profile. Moreover, opioids are less effective for managing certain types of pain, such as **neuropathic pain**, which arises from damage to the nervous system itself rather than peripheral injury. Neuropathic pain can manifest as burning, tingling, or shooting sensations and is often resistant to opioid treatment. Conditions like **fibromyalgia**, which is characterized by widespread musculoskeletal pain and tenderness, also present a challenge for conventional pain management, as opioids are generally ineffective in treating this condition. In these cases, **non-opioid analgesics** and **adjuvant therapies** such as **antidepressants** and **anticonvulsants** may offer better results, but they come with their own set of limitations and side effects [5].

In response to these challenges, researchers have sought to develop novel therapeutic strategies that are more specific, effective, and safer. The focus has shifted from simply providing pain relief to identifying and targeting the underlying mechanisms of pain at a molecular level. For example, the discovery of specific **pain receptors**, such as **TRPV1** (a receptor involved in the perception of heat and inflammation), and **Nav1.7** (a voltage-gated sodium channel crucial for transmitting pain signals) has opened new avenues for the development of pain therapies that target these receptors directly. Similarly, targeting **glutamate receptors** or **cannabinoid receptors** has shown promise in treating neuropathic pain and reducing inflammation without the risk of addiction associated with opioids. In addition to receptor-based therapies, research has also focused on **gene therapy**, **biologic agents**, and **neuromodulation techniques** as potential approaches to chronic pain [6-7]. Gene therapy involves the use of viruses or other delivery systems to introduce therapeutic genes into the nervous system, with the goal of correcting or modulating pain pathways at a genetic level. Biologic agents, such as **monoclonal antibodies** targeting specific inflammatory mediators like **CGRP** (calcitonin gene-related peptide) for migraine, offer a targeted approach to pain relief with fewer side effects. Neuromodulation therapies, such as **spinal cord stimulation** and **transcranial magnetic stimulation (TMS)**, provide non-pharmacological treatment options for patients with refractory pain. Despite these advancements, several obstacles remain in pain management, including **individual variability** in response to treatment, the **long-term safety** of newer therapies, and the need for more **personalized approaches**. For instance, while certain drugs may be effective for some individuals, they may be ineffective or cause intolerable side effects in others. The development of more personalized therapies, based on a

patient's genetic, environmental, and psychological factors, is a promising area of future research [7-10].

2. Mechanisms of Pain and the Nervous System

Pain is a complex, multifaceted sensory and emotional experience that plays a critical role in protecting the body from harm by signaling potential injury or damage. The perception of pain begins when specialized sensory neurons, called **nociceptors**, detect noxious stimuli. These nociceptors are activated by harmful or potentially harmful factors, such as extreme temperatures, mechanical pressure, or chemical irritants. They are located throughout the body, in tissues such as the skin, muscles, joints, and internal organs. Once activated, nociceptors generate electrical signals, which travel through **afferent nerve fibers**—specifically **A-delta fibers** and **C fibers**—to the **spinal cord**, where the pain signals are further processed and relayed to the brain for interpretation [10-12]. Pain processing is a highly intricate network involving sensory neurons, spinal cord circuits, and various regions of the brain. Once the signal reaches the spinal cord, it can be modulated before being sent to higher brain centers for more complex processing, including emotional and cognitive responses. The brain regions responsible for interpreting pain include the **somatosensory cortex**, which processes the sensory aspects of pain, and the **limbic system**, which processes the emotional and behavioral reactions to pain [13].

Pain is commonly classified into two main types: **nociceptive pain** and **neuropathic pain**, which have distinct mechanisms. **Nociceptive pain** occurs when tissue damage or inflammation activates nociceptors, leading to the transmission of pain signals. Nociceptors in this case respond to various harmful stimuli such as heat, pressure, or chemical mediators released during inflammation. Key receptors involved in nociceptive pain include **TRPV1** (Transient Receptor Potential Vanilloid 1) receptors, which are activated by heat and chemical irritants like capsaicin, and **P2X receptors**, which respond to ATP, released when cells are injured or damaged. **NMDA receptors** (N-methyl-D-aspartate receptors), on the other hand, are involved in **central sensitization**, a process where the spinal cord and brain become more responsive to pain stimuli, amplifying the pain experience [14-15]. This phenomenon is especially important in inflammatory pain, where prolonged pain signaling contributes to chronic pain states. In contrast, **neuropathic pain** arises from damage or dysfunction in the nervous system itself, either in the **peripheral nerves** or the **central nervous system**. This type of pain is typically persistent and involves altered neural processing that leads to an abnormal pain experience. Neuropathic pain is often associated with **central sensitization**, where the nervous system becomes hyper-responsive to even normal stimuli, and the perception of pain persists long after the original injury has healed. Conditions such as **diabetic neuropathy**, **post-herpetic neuralgia**, and **sciatica** are common examples of neuropathic pain. Neuropathic pain often involves changes in the neural circuitry of the spinal cord and brain, including **reorganization** of these circuits, which leads to an abnormal interpretation of sensory input. Unlike nociceptive pain, which is typically localized to the site of injury, neuropathic pain often manifests as burning, tingling, or shooting sensations that can occur without any visible injury [15-20].

The transmission of pain signals from the periphery to the spinal cord and ultimately to the brain involves various neurotransmitters, ion channels, and receptors. **Substance P**, a neuropeptide, plays a key role in the spinal cord, amplifying the pain signal as it is transmitted from the nociceptors to higher pain centers in the brain. Another critical neurotransmitter in pain transmission is **glutamate**, the primary excitatory neurotransmitter in the nervous system. Glutamate activates **NMDA receptors** in the spinal cord and brain, contributing to **central sensitization**, where the nervous system becomes more responsive to pain over time. **CGRP** (calcitonin gene-related peptide), released from sensory neurons, has also been implicated in pain transmission, particularly in **migraine** and **inflammatory pain**, where it leads to the dilation of blood vessels and further sensitizes pain pathways. **GABA** (gamma-aminobutyric acid), the main inhibitory neurotransmitter in the central nervous system, helps to suppress pain by inhibiting pain transmission at the spinal cord and brain level [20-22]. A decrease in GABAergic inhibition can lead to increased excitability of pain circuits, contributing to chronic pain. The transmission and modulation of pain signals in the body involve a complex interplay of these

various molecular players. At the peripheral level, the activation of nociceptors and the release of neurotransmitters such as substance P and glutamate help to propagate pain signals to the spinal cord. Once these signals reach the spinal cord, they can be modulated by both excitatory and inhibitory signals, determining the intensity and duration of the pain experience. The central nervous system, including the brain, further processes these pain signals, integrating sensory, emotional, and cognitive responses, which can influence the perception of pain. Understanding the detailed mechanisms of pain transmission and processing at the molecular, cellular, and neural levels provides insight into potential targets for pharmacological intervention. By targeting specific receptors, ion channels, and neurotransmitters involved in pain signaling, new therapies can be developed to more effectively manage both acute and chronic pain, offering patients more precise and personalized treatment options. These advances in pain neuropharmacology are crucial for developing better, safer therapies that address the underlying causes of pain while minimizing side effects [23-25].

3. Traditional Pain Management Therapies

Pain management has historically relied on a variety of therapeutic approaches to alleviate discomfort, including **non-steroidal anti-inflammatory drugs (NSAIDs)**, **opioids**, and **local anesthetics**. These treatments primarily aim to target either the peripheral mechanisms of pain, such as inflammation, or to suppress **central sensitization**, a phenomenon where the nervous system becomes more responsive to pain signals. Despite their effectiveness in treating many individuals, these therapies come with limitations and significant side effects, underlining the need for more targeted, safer alternatives. **NSAIDs**, such as **ibuprofen** and **aspirin**, are commonly used for managing mild to moderate pain, especially when inflammation is a contributing factor. They work by inhibiting **cyclooxygenase (COX) enzymes**, which are responsible for the production of **prostaglandins**—lipid molecules that mediate inflammation and sensitize nociceptors (pain receptors). By reducing the synthesis of prostaglandins, NSAIDs decrease the sensitivity of nociceptors and help alleviate pain. However, while effective, NSAIDs are not without their drawbacks. Long-term use, especially at high doses, can lead to serious **gastrointestinal issues**, including **ulcers** and **gastric bleeding**, as well as **renal toxicity** and other systemic effects. Additionally, NSAIDs do not address certain types of pain, particularly **neuropathic pain** or pain driven by **central sensitization**, where the nervous system itself becomes hyper-responsive to stimuli [26-27].

Opioids, such as **morphine**, **oxycodone**, and **fentanyl**, have long been the gold standard for managing moderate to severe pain. They work by binding to **opioid receptors** in the brain and spinal cord, specifically **mu**, **delta**, and **kappa** receptors, which are part of the body's endogenous pain control system. Activation of these receptors inhibits pain transmission and alters the emotional and sensory response to pain, producing powerful analgesia. While opioids are highly effective, their long-term use is associated with significant risks. The development of **tolerance** (requiring higher doses to achieve the same effect), **dependence**, and the potential for **addiction** have led to the opioid crisis, making them less desirable for chronic pain management. Furthermore, opioids come with a host of side effects, including **constipation**, **sedation**, **nausea**, and **respiratory depression**, the latter of which can be fatal. Despite these drawbacks, opioids remain a critical tool in the short-term management of acute pain and cancer-related pain, but the need for safer, non-addictive alternatives is more pressing than ever. **Local anesthetics**, such as **lidocaine**, provide a targeted approach to pain relief, particularly in the context of localized pain or surgical procedures. These drugs block **sodium channels** in nerve fibers, preventing the transmission of pain signals at the site of injury. By inhibiting the initiation and propagation of action potentials along nerves, local anesthetics effectively stop pain transmission locally without affecting the central nervous system. The advantage of local anesthetics is their **rapid onset** and **limited side effects**, particularly when compared to opioids or NSAIDs. However, their application is typically limited to localized pain, and they do not provide relief for widespread or chronic pain conditions. Furthermore, the relief provided by local anesthetics is often temporary, and they do not address the underlying causes of pain in chronic pain syndromes [28]. While these traditional therapies are effective for many types of pain, they each come with limitations that hinder their long-term use, particularly in the management of chronic or neuropathic pain. Opioids and

NSAIDs, in particular, carry risks of dependence, addiction, and adverse side effects, leading to a growing demand for more specific, targeted treatments. **Neuropathic pain**, for instance, which results from nerve damage, often does not respond well to opioids, and conditions involving **central sensitization** (where the nervous system becomes hyper-responsive) are also difficult to manage with these traditional drugs. This has led to the exploration of novel therapeutic strategies, including those that target specific **molecular pathways** involved in pain signaling, as well as **non-pharmacological approaches** such as **neuromodulation** and **cognitive-behavioral therapy [29]**.

4. New Insights and Emerging Therapeutic Approaches

Recent research in the neuropharmacology of pain has revealed novel molecular targets and mechanisms that are transforming pain management. These new insights are enabling the development of more effective therapies that can modulate the pain pathway at specific sites, offering better pain relief with fewer side effects compared to traditional treatments. A key area of focus in pain management research is ion channel modulators. Ion channels play a crucial role in the generation and propagation of pain signals. Voltage-gated sodium channels, particularly Nav1.7, are critical in transmitting pain signals in sensory neurons. Nav1.7 is involved in the initiation of action potentials in response to noxious stimuli. This channel's activation is essential for pain transmission, and targeting Nav1.7 with specific inhibitors holds great potential in treating pain without affecting normal neuronal activity. For example, researchers are studying Nav1.7 inhibitors for their ability to block pain transmission specifically, providing targeted pain relief while avoiding broader disruptions in nerve function. In addition to sodium channels, TRPV1 receptors, which are activated by heat and chemical irritants like capsaicin, are important in the perception of pain, particularly in inflammatory and neuropathic pain. TRPV1 antagonists are being developed to block the activation of these receptors, offering relief from conditions involving persistent pain, such as inflammatory and neuropathic pain [30].

Another exciting area of research focuses on targeting receptors and neurotransmitters involved in pain signaling. NMDA receptors, which are key players in central pain processing, have been extensively studied for their role in central sensitization—a process where pain perception becomes exaggerated due to long-term changes in the central nervous system. Drugs that block NMDA receptors, such as ketamine, have shown promise in treating neuropathic pain, as they inhibit the actions of glutamate, the major excitatory neurotransmitter in pain pathways. By blocking glutamate's action, ketamine and similar NMDA receptor antagonists can reduce the amplification of pain signals and prevent the development of chronic pain states. Additionally, CGRP (calcitonin gene-related peptide), a neuropeptide involved in the dilation of blood vessels and the transmission of pain signals, has been found to play a significant role in migraine and inflammatory pain. Drugs targeting CGRP receptors, such as erenumab, are now used in migraine management, providing relief by blocking the vasodilation and inflammation caused by CGRP signaling. These CGRP receptor antagonists are part of a new class of treatments for migraine, offering an alternative to traditional migraine medications with fewer side effects [31].

The endocannabinoid system (ECS) also plays a significant role in pain modulation. The ECS consists of cannabinoid receptors (CB1 and CB2), endogenous ligands such as anandamide and 2-AG, and enzymes that regulate the synthesis and breakdown of these ligands. CB1 receptors are mainly found in the central nervous system, while CB2 receptors are located in the peripheral nervous system and immune cells. The activation of these receptors by endocannabinoids or exogenous cannabinoids can modulate pain perception and reduce inflammation. Cannabinoid-based therapies, such as CBD oil, are being explored as potential alternatives to opioids, offering pain relief without the addictive properties. CBD (cannabidiol), unlike THC (tetrahydrocannabinol), does not produce the psychoactive effects associated with cannabis, making it an attractive option for pain management. Clinical studies have suggested that cannabinoids may be effective for conditions like chronic pain, arthritis, and multiple sclerosis-related pain, offering new hope for patients who do not respond well to traditional treatments. By interacting with the ECS, cannabinoid therapies may reduce pain and inflammation without the risks of opioid use [32].

5. Challenges and Future Directions

Despite the promising developments in the field of pain management, significant challenges remain that need to be addressed before emerging therapies can be widely adopted. One of the foremost hurdles is the **complexity of the pain pathway**. Pain is not a simple sensation but a multifactorial experience involving a network of sensory neurons, spinal cord processing, and brain interpretation. The complexity of this system means that any single therapeutic approach may not work for all types of pain. The way pain is processed can vary from one individual to another, influenced by genetic, environmental, and psychological factors. This individual variability in pain perception complicates the development of universally effective treatments. What works for one patient may not necessarily work for another, and understanding these nuances is essential to developing more personalized and effective therapies. **Personalized treatment plans** are a critical aspect of future pain management strategies. The future of pain relief lies in tailoring therapies to the specific needs of individual patients based on their genetic profile, pain history, and response to previous treatments. Personalization can be achieved by leveraging advances in **genomic medicine**, where genetic and molecular markers may be identified that predict which pain pathways are most active in a given patient. This approach would allow clinicians to choose the most appropriate treatment based on the underlying biology of a patient's pain, improving outcomes and minimizing adverse effects [33]. However, the implementation of personalized pain management remains challenging due to the complexity of pain biology and the lack of universally accepted biomarkers for different pain types. Another significant challenge involves the **pharmacokinetics** (how the body absorbs, distributes, metabolizes, and excretes a drug) and **pharmacodynamics** (the effects of the drug on the body) of new drugs. Developing new pain medications with favorable pharmacokinetic and pharmacodynamic profiles is crucial. Many promising compounds still face difficulties related to bioavailability, how long they remain effective in the body, and how they interact with other medications. For example, a drug may have excellent pain-relieving properties but could be rapidly metabolized, reducing its effectiveness. Similarly, a drug that targets specific pain pathways may cause unintended side effects in other parts of the body, such as gastrointestinal irritation, liver toxicity, or central nervous system depression. Therefore, the **safety profile** of new pain drugs must be thoroughly evaluated, requiring extensive preclinical and clinical research. Long-term safety is also a significant concern, especially as chronic pain is often treated with medications over long periods. Potential issues such as **drug tolerance**, **dependence**, and **adverse long-term effects** need to be carefully monitored to ensure that new therapies do not introduce new risks to patients [33-35].

Given the limitations of individual treatments, there is a growing recognition of the need for **multimodal pain management**. This approach combines different pharmacological agents with **non-pharmacological treatments** to enhance the effectiveness of pain relief and reduce the reliance on any single type of therapy. For instance, **cognitive-behavioral therapy (CBT)** can be used to address the psychological aspects of chronic pain, helping patients cope with the emotional and behavioral challenges that pain presents. **Physical therapy** and **exercise** are also integral components of multimodal approaches, especially for musculoskeletal and certain chronic pain conditions. **Neuromodulation techniques**, such as **spinal cord stimulation**, **transcranial magnetic stimulation (TMS)**, and **deep brain stimulation**, are increasingly being used in conjunction with pharmacological treatments to modulate pain signaling in the central nervous system. The future of pain management lies in the combination of innovative pharmacological approaches with these non-pharmacological treatments. As research continues, the integration of multimodal strategies will become more personalized, with clinicians combining different therapeutic approaches based on individual patient needs and pain types. However, achieving this requires overcoming the barriers of complexity, variability in response, and the need for personalized treatments. Additionally, ongoing research will need to focus on the development of **new biomarkers** to predict pain treatment responses, improving our ability to select the most effective therapies for each patient [35-40].

6. Conclusion

The neuropharmacology of pain management has evolved significantly over the years, with numerous advancements in understanding the molecular mechanisms underlying pain. While traditional therapies remain essential, new insights into pain signaling pathways have paved the way for innovative drug classes, including ion channel modulators, NMDA antagonists, and cannabinoid-based therapies. However, challenges such as drug efficacy, side effects, and the need for individualized treatment strategies continue to shape the field. As research progresses, new pharmacological and non-pharmacological approaches will likely provide better, more effective solutions for both acute and chronic pain management, ultimately improving the quality of life for millions of patients worldwide.

References

1. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. International journal of adolescent medicine and health. 2021 Jul 22;34(2):1-9.
2. Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, Phukan S. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria journal of medicine. 2017 Jul 11;53(2):151-6.
3. Zehravi M, Maqbool M, Ara I. Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview. International Journal of Adolescent Medicine and Health. 2021 Jun 18;33(6):339-45.
4. Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer: Targets and Therapy. 2022 Jan 11:15-24
5. Rasool S, Maqbool M. An overview about Hedychium spicatum: a review. Journal of Drug Delivery and Therapeutics. 2019 Feb 15;9(1-s):476-80.
6. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):367-73.
7. Maqbool M, Gani I, Dar MA. Anti-diabetic effects of some medicinal plants in experimental animals: a review. Asian Journal of Pharmaceutical Research and Development. 2019 Feb 15;7(1):66-9.
8. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. International journal of adolescent medicine and health. 2021 Apr 21;33(6):333-7.
9. Mohd M, Maqbool M, Dar MA, Mushtaq I. Polycystic ovary syndrome, a modern epidemic: an overview. Journal of Drug Delivery and Therapeutics. 2019 May 15;9(3):641-4.
10. Maqbool M, Fekadu G, Jiang X, Bekele F, Tolossa T, Turi E, Fetensa G, Fanta K. An up to date on clinical prospects and management of osteoarthritis. Annals of Medicine and Surgery. 2021 Dec 1;72:103077.
11. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. Journal of Drug Delivery and Therapeutics. 2019 Mar 15;9(2):520-7.
12. Zehravi M, Maqbool M, Ara I. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. Open Health. 2022 May 2;3(1):60-5.
13. Maqbool R, Maqbool M, Zehravi M, Ara I. Menstrual distress in females of reproductive age: a literature review. International journal of adolescent medicine and health. 2021 Jul 22;34(2):11-7.
14. Ara I, Maqbool M, Fekadu G, Hajam TA, Dar MA. Pharmaceutical significance of Nigella sativa L., a wonder herb. Journal of Applied Pharmaceutical Sciences and Research. 2020;3(4):04-13.

15. Maqbool M, Nasir N, Mustafa S. Polycystic in ovarian syndrome and its various treatment strategies. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2018 Sep 1;5(9):8470-8.

16. Maqbool M, Zehravi M, Maqbool R, Ara I. Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital, Srinagar, Jammu & Kashmir, India. CELLMED. 2021;11(2):8-1.

17. Ara I, Maqbool M, Bukhari B, Ara N, Hajam TA. Present status, standardization and safety issues with herbal drugs. International Journal of Research in Pharmaceutical Sciences and Technology. 2020 May 18;1(3):95-101.

18. Ara I, Maqbool M, Gani I. Reproductive Health of Women: implications and attributes. International Journal of Current Research in Physiology and Pharmacology. 2022 Nov 28:8-18.

19. Zehravi M, Maqbool R, Maqbool M, Ara I. To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India. Journal of Pharmaceutical Research International. 2021 Jun 10;33(31A):135-40.

20. Maqbool M, Javed S, Bajwa AA. Assessment OF pain management IN postoperative cases using different scales and questionnaires. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2019 Jan 1;6(1):983-7.

21. Ara I, Maqbool M, Zehravi M. Psychic consequences of infertility on couples: A short commentary. Open Health. 2022 Jan 1;3(1):114-9.

22. Bashir R, Maqbool M, Ara I, Zehravi M. An In sight into Novel Drug Delivery System: In Situ Gels. CELLMED. 2021;11(1):6-1.

23. Zehravi M, Maqbool M, Ara I. Teenage menstrual dysfunction: an overview. International Journal of Adolescent Medicine and Health. 2022 Sep 19;35(1):15-9.

24. Ara I, Zehravi M, Maqbool M, Gani I. A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries. Journal of Pharmaceutical Research & Reports. SRC/JPRSR-131. DOI: doi. org/10.47363/JPRSR/2022 (3). 2022;127.

25. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8254-9.

26. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8163-+.

27. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8070-6.

28. Maqbool M, Ikram U, Anwar A. Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8060-5.

29. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):357-66.

30. Zehravi M, Maqbool M, Ara I. An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India. The Indian Journal of Nutrition and Dietetics. 2021 Jul:408-18.

31. Maqbool M, Zehravi M. Neuroprotective role of polyphenols in treatment of neurological disorders: A review. Interventional Pain Medicine and Neuromodulation. 2021 Dec 31;1(1).

32. Maqbool M, Ara I, Gani I. The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age. International Journal of Current Research in Physiology and Pharmacology. 2022 Nov 28:19-31.

33. Maqbool M, Gani I. Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review. Journal of Pharmacy Practice and Community Medicine. 2018;4(4).

34. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):357-66.

35. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8070-6.

36. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8163-+.

37. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8254-9.

38. Qadrie Z, Maqbool M, Dar MA, Qadir A. Navigating challenges and maximizing potential: Handling complications and constraints in minimally invasive surgery. Open Health. 2025 Feb 5;6(1):20250059.

39. Oral O, Maqbool M, Thapa P, Tatlibal P, Enser M. The potential impact of weight control management on metabolic health during healthy aging. Global Translational Medicine. 2025 Jan 13:4815.

40. Maqbool M, Oral O. Implications of hypothyroidism in females of reproductive age: a review of current literature.